Latest Food and Drug Administration Stories
According to a recent medical study, various forms of dietary supplements have been found to be the culprit of more than 50 percent of the Food and Drug Adminstration’s (FDA) Class I Pharmaceutical recalls between 2004 and 2012. Kiley Law Group defective product attorneys comment on massive recalls and the damage the affects have on consumer health and trust. Andover, Massachusetts (PRWEB) May 20, 2013 According to a recent medical study (Jama Internal Medicine April 15, 2013), various...
DrugRisk is the Web’s largest source for information on prescription drug warnings, side effects and legal news. Visit http://www.DrugRisk.com Los Angeles, CA (PRWEB) May 20, 2013 The diabetes drug safety advocates at DrugRisk.com are announcing new information on the site for those taking the medications Januvia or Janumet. The FDA is investigating whether these drugs are related to cancer after a study found pre-cancerous cell growth in patients who had died*. DrugRisk was created to...
A recent CBS News article explores various proposed steps to increase the safety of indoor tanning salons. Dr. Simon Ourian of Epione Beverly Hills says that the FDA proposals are long overdue. Los Angeles, CA (PRWEB) May 20, 2013 According to a May 6, 2013 CBS News article, titled “FDA Wants Cancer Warnings at Indoor Tanning Salons,” tanning salons in the US may soon have to face stricter safety regulations. The Food and Drug Administration wants to see cancer warnings on indoor...
SEOUL, South Korea, May 20, 2013 /PRNewswire/ -- RNL BIO Co. Ltd., a stem cell biotechnology company dedicated to the commercialization of autologous cell therapy products for a variety of degenerative, ischemic and other indications, announces the availability of adult stem cell banking in the United States beginning on June 20, 2013. RNL BIO previously offered these services through another company, but will now provide the latest, safest technologies directly. As the sole global...
WELLINGTON, Fla., May 20, 2013 /PRNewswire/ -- Embark Holdings, Inc. (OTC: EMBK) announces that its wholly owned subsidiary Muscle Warfare, Inc. has passed a recent FDA inspection entitled an EIR (Establishment Inspection Report). The inspection was conducted to confirm that Muscle Warfare had discontinued the use of DMAA as stated in a response letter dated back to May of 2012. The inspection also included a complete facility inspection, which reviewed written and executed standard...
NEW YORK, May 18, 2013 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential securities fraud at AVEO Pharmaceuticals, Inc. ("AVEO" or the "Company") (NASDAQ: AVEO). (Logo: http://photos.prnewswire.com/prnh/20120119/MM38856LOGO ) The investigation focuses on whether the Company and its executives violated federal securities laws by issuing materially false and/or misleading statements regarding the Company's Phase III drug...
The DrugRisk Resource Center is the Web’s largest source for information on prescription drug warnings, side effects and legal news. Visit http://www.DrugRisk.com Chicago, IL (PRWEB) May 17, 2013 The prescription drug resource center DrugRisk.com is alerting patients taking the blood thinner Pradaxa of updated news on the site. A federal panel recently advised that the number of claims alleging internal bleeding has nearly tripled in the past few months*. DrugRisk was created to improve...
- IIMD China 2013 Hot Topics Preview SHANGHAI, May 17, 2013 /PRNewswire/ -- Medical devices are any medical items that are neither a drug nor a biological product. In light of their different mechanisms, actions and regulatory requirements, medical device (MD) trail evaluations are much more complicated than drug trails due to their unique clinical practices. Currently, the EMEA only evaluates MD safety instead of evaluating both safety and efficacy (which is left to the...
SAN DIEGO and CAMBRIDGE, Mass., May 17, 2013 /PRNewswire/ -- Shareholder rights attorneys at Robbins Arroyo LLP announce that a purchaser of Aveo Pharmaceutical, Inc. (NASDAQGS: AVEO) securities has filed a complaint in the U.S. District Court for the District of Massachusetts. The complaint alleges that Aveo and certain of its officers violated the Securities Exchange Act of 1934 (the "Exchange Act") between January 3, 2012 and May 1, 2013 (the "Class Period"). (Logo:...
WASHINGTON, May 17, 2013 /PRNewswire-USNewswire/ -- Personalized medicine and targeted therapies hold great potential to improve patient care and health care efficiency. At the Ninth Annual State of Personalized Medicine Luncheon hosted by the Personalized Medicine Coalition (PC), Janet Woodcock, M.D., Director, Center for Drug Evaluation and Research at the Food and Drug Administration (FDA), will discuss how the FDA is dealing with the expanding field of personalized medicine,...
Latest Food and Drug Administration Reference Libraries
The Chilean sea bass is the North American name for the Patagonian toothfish. The Chilean sea bass name derived in 1977 from Lee Lantz, a fish wholesaler looking for a more attractive name for the American fish market. In 1994 the Food and Drug Administration (FDA) accepted the Chilean sea bass as an alternative name for the Patagonian toothfish. This species is native to the southern Pacific, Atlantic, and Indian Oceans, around seamounts and continental shelves in the colder waters. The...
